Shokrollah Farrokhi - Department of Immunology and Allergy, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran and Department of Immunology and Allergy, The Persian Gulf Tropical and Infectious Diseases Research Centre, Bushehr University
Mohammad Ravanbod - Department of Immunology and Allergy, The Persian Gulf Tropical and Infectious Diseases Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran
Shahram Amiri - Department of Immunology and Allergy, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran and Department of Immunology and Allergy, The Persian Gulf Tropical and Infectious Diseases Research Centre, Bushehr University
Iraj Nabipour - Department of Endocrine and Metabolic Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran

The principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. This advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies (mAb). Radioactively-tagged antibodies which are applied in radioimmunotherapy (RIT), can target adjacent cells and may not require immune function. This study highlights the mechanism and the effect of action of radioimmunotherapic agents, especially two applied agents including 90Y-ibritumomab tiuxetan and 131I-tositumomab that are approved by Food and Drug Administration (FDA) for treatment of some cancers.

Radioimmunotherapy (RIT), Monoclonal antibodies (mAb), Cancer, 90Y-Ibritumomab tiuxetan, 131I-Tositumomab